COST OF TREATMENT WITH BIOSIMILARS - CASE WITH RITUXIMAB IN ONCOHEMATOLOGY

被引：0
|
作者：
Boncheva, E. [1 ]
Cherneva, D. [2 ]
Benisheva, T. [1 ]
机构：
[1] Med Univ Sofia, Sofia, Bulgaria
[2] Bulgarian Assoc Drug Informat, Sofia, Bulgaria
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC209
引用
收藏
页码：S148 / S149
页数：2
相关论文
共 50 条
  • [21] COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA
    Gironella, M.
    Gallardo-Escudero, J.
    Gomez-Barrera, M.
    Jarque, I
    Becares Martinez, F. J.
    Poveda, J. L.
    Martinez-Sesmero, J. M.
    Oyaguez, I
    HAEMATOLOGICA, 2019, 104 : 93 - 93
  • [22] Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case study
    Sharman, Jeff P.
    Kirchhoff, Carol F.
    Rifkin, Robert M.
    FUTURE ONCOLOGY, 2022, 18 (12) : 1499 - 1510
  • [23] Progress in treatment in oncohematology (an attempt of critical reflections)
    Sulek, Kazimierz
    ONCOLOGY IN CLINICAL PRACTICE, 2005, 1 (01): : 7 - 9
  • [24] DOES INCLUDING BIOSIMILARS EARLIER IN THE TREATMENT PATHWAYS LEAD TO COST SAVINGS IN RHEUMATOLOGY?
    Tak, S.
    Methuku, M.
    VALUE IN HEALTH, 2023, 26 (12) : S287 - S287
  • [25] Challenges in developement of cost effective biosimilars
    Gadgil, Himanshu S.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [26] Comparison of Adverse Event Profiles of Rituximab, Rituximab Hycela and Rituximab Biosimilars: A Real-World Pharmacovigilance Database Analysis
    Keerty, Dinesh
    Ananthaneni, Anil
    Ramadas, Poornima
    Master, Samip R.
    BLOOD, 2022, 140 : 13196 - 13197
  • [27] Safety of switching between rituximab biosimilars in onco-hematology
    Urru, Silvana A. M.
    Spila Alegiani, Stefania
    Guella, Anna
    Traversa, Giuseppe
    Campomori, Annalisa
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [28] Uptake of Rituximab Biosimilars in Medicare and Medicaid in 2019-2022
    Qian, Jingjing
    AMERICAN JOURNAL OF MANAGED CARE, 2024, 30 (12): : e359 - e363
  • [29] Safety of switching between rituximab biosimilars in onco-hematology
    Silvana A. M. Urru
    Stefania Spila Alegiani
    Anna Guella
    Giuseppe Traversa
    Annalisa Campomori
    Scientific Reports, 11
  • [30] The impact of data extrapolation on publication planning for etanercept and rituximab biosimilars
    Reardon, Tony
    Caldwell, Ben
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 : 38 - 38
12345